FRISQ today published a Q&A on the UK health care market and its approach, provided by FRISQ’s UK director Roger Evans.
During Q2, the development team has continued the effort to significantly improve the performance and scalability of the core FRISQ platform. The success of this can be seen from the recently announced deal with Capio Elderly and Mobile Care, the increased interest with a Pharmaceutical focused offering and initial traction in the UK (see below).From a functionality point of view, the platform now makes it possible for patient reported data to be used, subject to explicit approval, in a clinical...
CEO Statement FRISQ’s Capital Markets Day in May was a great opportunity to present where we are and where we are moving to. We could then, and can now, report that higher recurring revenues have had a positive effect on cash flow, along with a cost control that has shifted funds from administration to development and commercialization. That shift also includes increasing sales staff and expanding footprints in the UK. We were then also able to present our innovative work with the platform; how w...
FRISQ (NASDAQ: "FRISQ") has signed a commercial agreement with Capio Elderly and Mobile Care. The agreement runs for 5 years and the order value amounts to SEK 15 million. The agreement enters into force on 1 July 2021 and replaces the previous pilot agreement, after FRISQ Care has been evaluated in competition with other systems.
CEO Statement The pandemic continues to affect our industry in many ways. But although the room for long-term digitalisation decisions is small right now, FRISQ’s pilot projects continue to run as planned or better. Our clients’ innovation continue to depend heavily on FRISQ Care and we have in several instances been asked to increase our involvement. The feedback from care professionals on our ongoing product developments, is very encouraging. The burden of administrative tasks is reduced, pat...
The shareholders of Frisq Holding AB (publ), reg. no. 556959-2867, (the "Company"), are hereby convened to the annual general meeting to be held on Friday 26 February 2021, at 14.00 at Baker & McKenzie's premises at Vasagatan 7 in Stockholm.